GlassScriptPhysician profile
Reena Mary Thomas
NPI 1154640423
$242.85
in general payments reported to CMS, 2019-2025
12 companies · $46.62 in 2025
The $46.62 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.59 · 2021: $55.95 · 2022: $52.88 · 2023: $14.04 · 2024: $46.77 · 2025: $46.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $32.62 | 2021-2022 | |
| Amgen INC. | $30.51 | 2019-2025 | Evenity |
| Ucb, INC. | $27.27 | 2021 | |
| Ardelyx, INC. | $23.64 | 2024 | Ibsrela |
| Abbvie INC. | $23.13 | 2024 | |
| Amneal Pharmaceuticals LLC | $21.93 | 2022 | |
| Novo Nordisk INC | $15.70 | 2025 | |
| Biogen, INC. | $14.04 | 2023 | Vumerity |
| Lundbeck LLC | $13.95 | 2025 | Vyepti |
| Braintree Laboratories, INC. | $13.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.